Levodopa

Routes
Oral (PO)
Half-Life (t½)
PO: 1.5h
Formula
C9H11NO4
Molecular Weight
197.19 g/mol
PubChem CID
6047
Aliases
L-DOPA, L-3,4-dihydroxyphenylalanine

Pharmacological Mechanism

Dopamine prodrug — crosses the BBB via LAT1 (dopamine does not). Decarboxylated by AADC to dopamine both centrally and peripherally. Carbidopa (peripheral AADC inhibitor) is co-administered to prevent peripheral dopamine formation (nausea, hypotension) and preserve more L-DOPA for CNS conversion.

Half-Life & Elimination Curve (PO: 1.5h)

100%50%25%12.5%0%0h0×t½1.5h1×t½3h2×t½4.5h3×t½6h4×t½7.5h5×t½0×t½ (0h): 100% remaining (~0.883 mg/L)1×t½ (1.5h): 50% remaining (~0.442 mg/L)2×t½ (3h): 25% remaining (~0.221 mg/L)3×t½ (4.5h): 12.5% remaining (~0.11 mg/L)4×t½ (6h): 6.3% remaining (~55.2 µg/L)5×t½ (7.5h): 3.1% remaining (~27.6 µg/L)
Plasma (PO)t½ Decay (1.5h)Effect Site (ke0)
  • 0×t½0h100% (0.883 mg/L)
  • 1×t½1.5h50% (0.442 mg/L)
  • 2×t½3h25% (0.221 mg/L)
  • 3×t½4.5h12.5% (0.11 mg/L)
  • 4×t½6h6.3% (55.2 µg/L)
  • 5×t½7.5h3.1% (27.6 µg/L)
Elimination t½1.5h (PO)
Rate Constant (ke)0.462 h⁻¹
Time to Peak (Tmax)1.44h
Est. Peak (Cmax)0.883 mg/L
Clearance (CL)32.3 L/h
97% Washout (5×t½)7.5h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Interactions

Chemical Structure & Identifiers

References